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Abstract
Background: The pathogenesis of primary tuberculous pleurisy is a delayed-type hypersensitivity immunogenic
reaction to a few mycobacterial antigens entering the pleural space rather than direct tissue destruction by
mycobacterial proliferation. Although it has been shown that pulmonary tuberculosis induces
18-fluorodeoxyglucose (FDG) uptake in active lesions, little is known about the application of FDG positron
emission/computed tomography (FDG PET/CT) to the management of primary tuberculous pleurisy.
Case presentation: We report a case of asymptomatic primary tuberculous pleurisy presenting with diffuse nodular
pleural thickening without distinct pleural effusion and parenchymal lung lesions mimicking malignant
mesothelioma. An initial FDG PET/CT scan demonstrated multiple lesions of intense FDG uptake in the right pleura
and thoracoscopic biopsy of pleural tissue revealed caseous granulomatous inflammation. The patient received
antituberculous therapy for 6 months, with clearly decreased positive signals on a repeated FDG PET/CT scan.
Conclusion: FDG PET/CT imaging may be useful for evaluating disease activity in tuberculous pleurisy patients with
an unknown time of onset.
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Background
18-fluorodeoxyglucose positron emission/computed tom-
ography (FDG PET/CT) is a noninvasive imaging tech-
nique that visualizes glucose metabolism and has been
regarded as useful for differentiating between benign and
malignant diseases [1,2]. However, it has been shown that
inflammatory disorders, especially pulmonary tuberculosis,
also induce FDG uptake in active lesions, which suggests
that FDG PET results should be interpreted with caution
[3-5]. Conventional or dual phase FDG PET can not effect-
ively distinguish malignant disease from mycobacterium
infections. Multi-tracer PET, a novel promising technology
utilizing differences in tracer kinetics and decay, has been
providing additional and complementary information to
improve pulmonary nodule characterization [5].
The usefulness of FDG PET in the detection of mycobac-
terium infection sites has been shown in patients with
miscellaneous infectious lesions or human immunodefi-
ciency virus-associated fever of unknown origin [6,7].
Moreover, it has been reported that FDG PET/CT is help-
ful not only for evaluating disease activity, but also for
monitoring therapeutic responses in pulmonary tubercu-
losis, tuberculous lymphadenitis, and skeletal tuberculosis,
particularly in smear-negative patients [5,8-10]. Via et al.
demonstrated that FDG-PET uptake in tuberculous pul-
monary lesions was significantly reduced with as little as
1 week of treatment prior to changes in the volume and
density of lesions in a rabbit model [11]. The absence of
reduced FDG PET uptake in the early phase of treat-
ment may suggest active tuberculosis due to a lack of
adherence, drug resistance, or misdiagnosis [9].
The pathogenesis of primary tuberculous pleurisy is a
delayed-type hypersensitivity immunogenic reaction to a
few mycobacterial antigens entering the pleural space ra-
ther than direct tissue destruction by mycobacterial pro-
liferation [12]. However, little is known about the
application of FDG PET/CT imaging to the management
of primary tuberculous pleurisy. We report here a case
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of asymptomatic primary tuberculous pleurisy with in-
tense FDG uptake mimicking malignant mesothelioma.
Case presentation
A 26-year-old man with no subjective symptoms was re-
ferred to our hospital because of a chest radiographic
abnormality in the right hemithorax on his chest X-ray
(Figure 1A), which was incidentally found during a college
health examination. Chest CT revealed diffuse nodular
thickening of the right pleura, without distinct pleural effu-
sion and parenchymal lung lesions, mimicking malignant
mesothelioma. An initial FDG PET/CT scan demon-
strated multiple lesions of intense FDG uptake in the right
pleura (maximal standard uptake value (SUVmax) = 10.9)
(Figure 2A and Figure 3A). He had no history of pulmon-
ary or autoimmune disease or occupational exposure to as-
bestos, silica, or other fibrogenic substances. Since the
pleural specimens obtained from CT-guided needle biopsy
were insufficient to allow for a definitive diagnosis, the pa-
tient was admitted for thoracoscopic biopsy.
On admission, right breath sounds were decreased.
Remaining physical examinations revealed no abnormal
findings. A full blood cell count, the results of liver and
renal function tests, and other data were within normal
limits. Thoracoscopic biopsy of the pleural tissue
revealed caseous necrosis and granulomatous inflamma-
tion (Figure 4), although acid-fast bacilli were not found
in biopsy specimens. Cultures of sputum and pleural tis-
sue were also negative. However, the QuantiFERON-TB
second generation (QFT-2G) test (3.02 IU/ml) and tu-
berculin skin test (10 mm induration) were both positive
based on the Japanese criteria.
Although no positive culture was obtained, other clin-
ical data suggested that a diagnosis of tuberculous pleur-
isy was highly likely in this case and the patient received
antituberculous therapy for 6 months (2HREZ/4HRE)
without any side effects. Just after chemotherapy, a
repeated FDG PET/CT scan revealed clearly decreased
positive signals (SUVmax = 5.7) with marked improve-
ments in pleural thickening (Figure 2B and Figure 3B).
Six months after the completion of chemotherapy, a
chest radiograph showed further improvements in
pleural based opacities relative to that taken just after
chemotherapy (Figure 1B and C).
Figure 1 Chest radiograph. A: Pleural based opacities in the right hemithorax at presentation. B: Marked improvements after 6 months of
antituberculous chemotherapy. C: Further improvements another 6 months after the completion of chemotherapy.
Figure 2 FDG PET image. A: Multiple lesions of intense FDG uptake in the right pleura at presentation. B: Clearly decreased positive signals after
6 months of antituberculous chemotherapy.
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Discussion
Pleural inflammation caused by bacteria, mycobacter-
ium, or autoimmune disease is usually characterized by
effusion, fever, malaise, chest pain, nonproductive cough,
and dyspnea in the acute phage [13], or diffuse thicken-
ing of the pleura, with or without calcification, in the
chronic phase. Therefore, pleural thickening with no
subjective symptoms generally implies non-active in-
flammatory pleural diseases, so-called “residual pleural
thickness”, or neoplasm of the pleura. Interestingly, the
asymptomatic diffuse pleural thickening in our case
showed intense FDG uptake and proved to be caseous
granulomatous inflammation.
Duysinx et al. suggested that FDG PET/CT is an effective
tool for differentiating between benign and malignant
pleural diseases. The uptake of FDG was intense in all
cases of mesothelioma and neoplastic pleurisy associated
with primary lung cancer. In contrast, FDG PET/CT im-
aging revealed an absence of FDG uptake within the pleura
of 2 of 3 patients with tuberculous pleurisy and the rest
showed moderate uptake, although detailed clinical data of
these patients were not described [14]. Kramer et al. also
evaluated the feasibility of PET in the diagnosis of pleural
thickening on CT. They concluded that qualitative assess-
ment with PET discriminates between malignant and be-
nign pleural thickening with high accuracy and a high
negative predictive value. However, there has been no de-
scription of tuberculous pleurisy [15]. To the best of our
knowledge, this is the first reported case of tuberculous
pleurisy with intense FDP uptake.
Figure 3 FDG PET/CT scan. A: Extensive nodular thickening of the right pleura at presentation showing intense FDG uptake without distinct
pleural effusion and parenchymal lung lesions. B: Marked improvements with decreased positive signals after 6 months of antituberculous
chemotherapy.
Figure 4 Pathological findings of pleural tissue. A: Caseous necrosis. B: Granulomatous inflammation.
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The pathogenesis of primary tuberculous pleurisy is a
delayed-type hypersensitivity immunogenic reaction to a
few mycobacterial antigens entering the pleural space ra-
ther than direct tissue destruction by uncontrolled myco-
bacterial proliferation [12]. This appears to be the reason
for the low rate of positive results in acid-fast staining of
pleural fluid and tissue, as seen in this case [16]. Recent
findings suggest that the immunogenic reaction in tubercu-
lous pleurisy involves lymphocytes (including CD3, CD4,
CCR4, and Th17 cells), neutrophils, mesothelial cells, and
various cytokines such as interferon-γ, interleukin (IL)-8,
IL-12, and monocyte chemoattractant protein-1 [17,18].
However, the complex mechanisms that induce high glu-
cose metabolism and show high uptake of FDG in pleural
thickening is unclear at this time.
About half of untreated cases of primary tuberculous
pleurisy relapse with more severe forms of active pul-
monary or extra-pulmonary tuberculosis, which may re-
sult in severe disability or death [19,20]. However, in
general, many cases of pleural thickening suspiciously
caused by primary tuberculous pleurisy with no subject-
ive symptoms have not received antituberculous chemo-
therapy. FDG uptake in the pleura with positive
QuantiFERON-TB may support the use of antitubercu-
lous treatment in such cases.
Conclusions
Active tuberculosis should be considered in the differen-
tial diagnosis of diffuse pleural thickening even when
there are no subjective symptoms. Moreover, FDG PET/
CT imaging may be useful for evaluating disease activity
and monitoring therapeutic responses in tuberculous
pleurisy patients with an unknown time of onset.
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